Rami S Komrokji1. 1. Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA. Rami.komrokji@moffitt.org.
Abstract
PURPOSE OF REVIEW: Alleviating cytopenias, namely anemia, is the main goal of therapy in lower-risk myelodysplastic syndromes (MDS). Current available treatment options remain limited. We review the role of TGF-B pathway in MDS, the current available data on luspatercept and sotatercept development. RECENT FINDINGS: TGF-B pathway is overactivated in MDS contributing to observed myelosuppression. SMADs, the downstream proteins of TGF-B pathway, are upregulated. GDF-11 is a negative regulator of terminal erythroid differentiation and an activin receptor ligand. Sotatercept and luspatercept are fusion ligand trap novel agents for activin II receptors A and B, respectively. Early promising results have been reported with those novel agents for treating anemia in lower-risk MDS patients, and higher responses were observed among patients with ring sideroblasts and SF3B1 mutation. A phase III randomized clinical trial with luspatercept was recently conducted. Activin receptor II ligand traps may represent a new paradigm for anemia treatment in MDS.
PURPOSE OF REVIEW: Alleviating cytopenias, namely anemia, is the main goal of therapy in lower-risk myelodysplastic syndromes (MDS). Current available treatment options remain limited. We review the role of TGF-B pathway in MDS, the current available data on luspatercept and sotatercept development. RECENT FINDINGS:TGF-B pathway is overactivated in MDS contributing to observed myelosuppression. SMADs, the downstream proteins of TGF-B pathway, are upregulated. GDF-11 is a negative regulator of terminal erythroid differentiation and an activin receptor ligand. Sotatercept and luspatercept are fusion ligand trap novel agents for activin II receptors A and B, respectively. Early promising results have been reported with those novel agents for treating anemia in lower-risk MDSpatients, and higher responses were observed among patients with ring sideroblasts and SF3B1 mutation. A phase III randomized clinical trial with luspatercept was recently conducted. Activin receptor II ligand traps may represent a new paradigm for anemia treatment in MDS.
Authors: Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian Journal: Blood Date: 2006-04-11 Impact factor: 22.113
Authors: Sutada Lotinun; R Scott Pearsall; Monique V Davies; Tod H Marvell; Travis E Monnell; Jeffrey Ucran; Roberto J Fajardo; Ravindra Kumar; Kathryn W Underwood; Jasbir Seehra; Mary L Bouxsein; Roland Baron Journal: Bone Date: 2010-01-18 Impact factor: 4.398
Authors: Jon Ruckle; Mark Jacobs; William Kramer; Amelia E Pearsall; Ravindra Kumar; Kathryn W Underwood; Jasbir Seehra; Yijun Yang; Carolyn H Condon; Matthew L Sherman Journal: J Bone Miner Res Date: 2009-04 Impact factor: 6.741
Authors: Li Zhou; Aaron N Nguyen; Davendra Sohal; Jing Ying Ma; Perry Pahanish; Krishna Gundabolu; Josh Hayman; Adam Chubak; Yongkai Mo; Tushar D Bhagat; Bhaskar Das; Ann M Kapoun; Tony A Navas; Simrit Parmar; Suman Kambhampati; Andrea Pellagatti; Ira Braunchweig; Ying Zhang; Amittha Wickrema; Satyanarayana Medicherla; Jacqueline Boultwood; Leonidas C Platanias; Linda S Higgins; Alan F List; Markus Bitzer; Amit Verma Journal: Blood Date: 2008-05-12 Impact factor: 22.113
Authors: Roger M Lyons; Thomas M Cosgriff; Sanjiv S Modi; Robert H Gersh; John D Hainsworth; Allen L Cohn; Heidi J McIntyre; Indra J Fernando; Jay T Backstrom; C L Beach Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Nianhang Chen; Nastya Kassir; Abderrahmane Laadem; Stephen E Maxwell; Priya Sriraman; Ana Carolina Giuseppi; Steve Ritland; Peter G Linde; Balasubrahmanyam Budda; Joseph G Reynolds; Simon Zhou; Maria Palmisano Journal: CPT Pharmacometrics Syst Pharmacol Date: 2020-06-30
Authors: Sarah Parisi; Carlo Finelli; Antonietta Fazio; Alessia De Stefano; Sara Mongiorgi; Stefano Ratti; Alessandra Cappellini; Anna Maria Billi; Lucio Cocco; Matilde Y Follo; Lucia Manzoli Journal: Int J Mol Sci Date: 2021-01-15 Impact factor: 5.923